|1.||Feng, Qiang: 5 articles (06/2009 - 03/2006)|
|2.||Xu, Jing: 4 articles (09/2014 - 06/2006)|
|3.||Chen, Zhi-Nan: 4 articles (09/2014 - 06/2006)|
|4.||Mi, Li: 4 articles (06/2007 - 03/2006)|
|5.||Zhu, Ping: 4 articles (06/2007 - 03/2006)|
|6.||Tian, Rong: 4 articles (06/2007 - 03/2006)|
|7.||Zhang, Yang: 3 articles (09/2014 - 03/2006)|
|8.||Li, Yu: 3 articles (06/2009 - 06/2006)|
|9.||Zhang, Qing: 3 articles (06/2007 - 06/2006)|
|10.||Song, Fei: 3 articles (06/2007 - 06/2006)|
|1.||Hepatocellular Carcinoma (Hepatoma)
01/01/2015 - "This study evaluated the safety and objective response of combining 131I-labeled-metuximab (Licartin) with transarterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC). "
01/01/2015 - "131 I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study."
09/01/2014 - "Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation."
08/01/2012 - "Hepatic artery injection of ¹³¹I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study."
12/21/2013 - "131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma."
|2.||Neoplasm Metastasis (Metastasis)
02/01/2007 - "We previously reported that Licartin ([131I] mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/CD147, was closely related to HCC invasion and metastasis. "
06/01/2007 - "Here, we investigated the function of HAb18G/CD147, a member of CD147 family, and its antibodies, HAb18 and LICARTIN, in HCC invasion and metastasis. "
06/01/2007 - "In an orthotopic model of HCC in nude mice, HAb18 and LICARTIN treatment effectively reduced the tumor growth and metastasis as well as the expression of three major factors in the HCC microenviroment (MMPs, vascular endothelial growth factor, and fibroblast surface protein) in the paracancer tissues. "
|3.||Liver Neoplasms (Liver Cancer)
09/01/2014 - "To assess the efficacy of combining radioimmunoconjugate [(131)I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0-B stage. "
01/01/2015 - "Owing to excellent tumor-targeting, promised efficacy and favourable toxicity profile, the novel combination therapy of licartin and TACE could be applied in patients with unresectable HCC."
01/01/2015 - "The radiobiological distribution demonstrated better localization of licartin in liver tumors than other tissues (P<0.01). "
09/01/2014 - "[(131)I] metuximab may yield prevention of tumor recurrence after RFA. "
10/01/2013 - "For all patients, licartin was first perfused into the tumor feeding artery and then the TACE procedure was performed 20 min later. "
02/01/2007 - "Licartin is a promising drug for preventing post-OLT tumor recurrence in advanced HCC patients excluded by the currently strict criteria for OLT. "
|5.||Body Weight (Weight, Body)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)